# Effect of APL180 on Endothelial Function in Familial Hypercholesterolemia Patients

> **NCT00751608** · PHASE2 · WITHDRAWN · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Familial Hypercholesterolemia

## Interventions

- **DRUG:** APL180
- **DRUG:** APL180
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00751608
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2006-09
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2016-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00751608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00751608, "Effect of APL180 on Endothelial Function in Familial Hypercholesterolemia Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00751608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*